This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jones, R. N.
Right arrow Articles by Sader, H. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jones, R. N.
Right arrow Articles by Sader, H. S.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, January 2007, p. 227-230, Vol. 45, No. 1
0095-1137/07/$08.00+0     doi:10.1128/JCM.01588-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Multicenter Studies of Tigecycline Disk Diffusion Susceptibility Results for Acinetobacter spp.{triangledown}

Ronald N. Jones,1,2* Mary Jane Ferraro,3 L. Barth Reller,4 Paul C. Schreckenberger,5 Jana M. Swenson,6 and Helio S. Sader1

JMI Laboratories, North Liberty, Iowa,1 Tufts University School of Medicine, Boston, Massachusetts,2 Massachusetts General Hospital, Boston, Massachusetts,3 Duke University Medical Center, Durham, North Carolina,4 Loyola University Medical Center, Maywood, Illinois,5 Centers for Disease Control and Prevention, Atlanta, Georgia6

Received 1 August 2006/ Returned for modification 10 October 2006/ Accepted 25 October 2006

Acinetobacter sp. isolates having multidrug resistance (MDR) patterns have become common in many medical centers worldwide, limiting therapeutic options. A five-center study tested 103 contemporary clinical Acinetobacter spp., including MDR strains, by reference broth microdilution and disk diffusion (15-µg disk content) methods against tigecycline. Applying U.S. Food and Drug Administration tigecycline breakpoint criteria for Enterobacteriaceae (susceptibility at ≤2 µg/ml [≤1 µg/ml by the European Committee on Antimicrobial Susceptibility Testing]; disk diffusion breakpoints at ≥19 mm and ≤14 mm) to Acinetobacter spp. led to an unacceptable error rate (23.3%). However, an adjustment of tigecycline disk diffusion breakpoints (susceptible/resistant) to ≥16/≤12 mm reduced intermethod errors to an acceptable level (only 9.7%, all minor).

* Corresponding author. Mailing address: JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317. Phone: (319) 665-3370. Fax: (319) 655-3371. E-mail: ronald-jones{at}jmilabs.com.

{triangledown} Published ahead of print on 8 November 2006.

Journal of Clinical Microbiology, January 2007, p. 227-230, Vol. 45, No. 1
0095-1137/07/$08.00+0     doi:10.1128/JCM.01588-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Akers, K. S., Mende, K., Yun, H. C., Hospenthal, D. R., Beckius, M. L., Yu, X., Murray, C. K. (2009). Tetracycline Susceptibility Testing and Resistance Genes in Isolates of Acinetobacter baumannii-Acinetobacter calcoaceticus Complex from a U.S. Military Hospital. Antimicrob. Agents Chemother. 53: 2693-2695 [Abstract] [Full Text]  
  • Canigia, L. F., Bantar, C. (2008). Susceptibility testing of tigecycline against Acinetobacter spp. by disc diffusion method: withdrawing a therapeutic option by varying the Mueller-Hinton agar?. J Antimicrob Chemother 62: 1463-1464 [Full Text]  
  • Curcio, D., Fernandez, F. (2008). Comment on: Effect of different Mueller-Hinton agars on tigecycline disc diffusion susceptibility for Acinetobacter spp.. J Antimicrob Chemother 62: 1166-1167 [Full Text]  
  • Valentine, S. C., Contreras, D., Tan, S., Real, L. J., Chu, S., Xu, H. H. (2008). Phenotypic and Molecular Characterization of Acinetobacter baumannii Clinical Isolates from Nosocomial Outbreaks in Los Angeles County, California. J. Clin. Microbiol. 46: 2499-2507 [Abstract] [Full Text]  
  • Peleg, A. Y., Seifert, H., Paterson, D. L. (2008). Acinetobacter baumannii: Emergence of a Successful Pathogen. Clin. Microbiol. Rev. 21: 538-582 [Abstract] [Full Text]  
  • Karageorgopoulos, D. E., Kelesidis, T., Kelesidis, I., Falagas, M. E. (2008). Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. J Antimicrob Chemother 62: 45-55 [Abstract] [Full Text]  
  • Perez, F., Hujer, A. M., Hujer, K. M., Decker, B. K., Rather, P. N., Bonomo, R. A. (2007). Global Challenge of Multidrug-Resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 51: 3471-3484 [Full Text]  
  • Curcio, D., Fernandez, F., Jones, R. N., Ferraro, M. J., Reller, L. B., Schreckenberger, P. C., Sader, H. S. (2007). Tigecycline Disk Diffusion Breakpoints of Acinetobacter spp.: a Clinical Point of View. J. Clin. Microbiol. 45: 2095-2096 [Full Text]  
  • Iredell, J., Thomas, L., Power, D., Mendes, E. (2007). Tigecycline resistance in Australian antibiotic-resistant Gram-negative bacteria. J Antimicrob Chemother 59: 816-818 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»